2-deoxy-d-glucose Drug

BDR Pharma on Monday said it has inked a licensing pact with the Defence Research and Development Organisation (DRDO) to manufacture, distribute, and market COVID-19 drug 2-Deoxy-D-Glucose (2-DG) in the country.

Drug firm Mankind Pharma today said it has received licence from the Defence Research and Development Organisation (DRDO) to manufacture and market oral 2-deoxy-D-glucose (2-DG), used for the treatment of COVID-19.

Dr Reddy's Laboratories today announced the commercial launch of 2-Deoxy-D-Glucose (2-DG) used to treat Covid patients, adding that the drug will be available across hospitals in metros and Tier 1 cities in the initial weeks.

The Defence Research and Development Organisation or DRDO, which developed 2-Deoxy-D-Glucose (2-DG), a drug used for treatment of COVID-19 patients, has called for Expression of Interest to transfer the technology to Indian pharmaceutical firms.

As India battles the second wave of Covid infections, an anti-Covid drug found to help speed up recovery and reduce oxygen dependence has been launched by the government.

The Defence Research and Development Organisation's (DRDO) new anti-COVID drug 2-DG should work against various strains of the COVID-19 virus, DRDO chairperson Dr G Satheesh Reddy said today.

The first batch of anti-COVID oral drug 2-DG, developed by the DRDO, was released on Monday by Defence Minister Rajnath Singh and Health Minister Harsh Vardhan.

BDR Pharma on Monday said it has inked a licensing pact with the Defence Research and Development Organisation (DRDO) to manufacture, distribute, and market COVID-19 drug 2-Deoxy-D-Glucose (2-DG) in the country.

Drug firm Mankind Pharma today said it has received licence from the Defence Research and Development Organisation (DRDO) to manufacture and market oral 2-deoxy-D-glucose (2-DG), used for the treatment of COVID-19.

Dr Reddy's Laboratories today announced the commercial launch of 2-Deoxy-D-Glucose (2-DG) used to treat Covid patients, adding that the drug will be available across hospitals in metros and Tier 1 cities in the initial weeks.

The Defence Research and Development Organisation or DRDO, which developed 2-Deoxy-D-Glucose (2-DG), a drug used for treatment of COVID-19 patients, has called for Expression of Interest to transfer the technology to Indian pharmaceutical firms.

As India battles the second wave of Covid infections, an anti-Covid drug found to help speed up recovery and reduce oxygen dependence has been launched by the government.

The Defence Research and Development Organisation's (DRDO) new anti-COVID drug 2-DG should work against various strains of the COVID-19 virus, DRDO chairperson Dr G Satheesh Reddy said today.

The first batch of anti-COVID oral drug 2-DG, developed by the DRDO, was released on Monday by Defence Minister Rajnath Singh and Health Minister Harsh Vardhan.